Alphatec (NASDAQ:ATEC) Reaches New 1-Year Low at $5.21

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) reached a new 52-week low during trading on Tuesday . The company traded as low as $5.21 and last traded at $5.24, with a volume of 474777 shares traded. The stock had previously closed at $5.56.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ATEC. Stifel Nicolaus dropped their price objective on Alphatec from $19.00 to $16.00 and set a "buy" rating on the stock in a research note on Thursday, August 1st. Piper Sandler lowered their target price on Alphatec from $17.00 to $12.00 and set an "overweight" rating on the stock in a research note on Thursday, August 1st. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a report on Friday, August 30th. Morgan Stanley lowered Alphatec from an "overweight" rating to an "equal weight" rating in a research note on Thursday, August 1st. Finally, Barclays started coverage on shares of Alphatec in a research report on Monday, July 8th. They set an "overweight" rating and a $19.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $17.50.

Alphatec Stock Performance

The firm has a market capitalization of $741.39 million, a P/E ratio of -3.56 and a beta of 1.40. The stock has a fifty day simple moving average of $6.71 and a two-hundred day simple moving average of $9.94. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.22 and a quick ratio of 1.21.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its earnings results on Wednesday, July 31st. The medical technology company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.03). Alphatec had a negative net margin of 33.48% and a negative return on equity of 816.57%. The firm had revenue of $145.57 million during the quarter, compared to the consensus estimate of $144.55 million. During the same period in the previous year, the firm earned ($0.43) earnings per share. The business's quarterly revenue was up 24.5% on a year-over-year basis. On average, research analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Insider Activity

In other Alphatec news, Director David M. Demski bought 50,000 shares of the business's stock in a transaction dated Wednesday, August 21st. The shares were purchased at an average price of $5.67 per share, for a total transaction of $283,500.00. Following the purchase, the director now directly owns 288,441 shares of the company's stock, valued at $1,635,460.47. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 22.80% of the company's stock.

Hedge Funds Weigh In On Alphatec

A number of large investors have recently modified their holdings of the company. Creative Planning increased its holdings in Alphatec by 112.7% during the 2nd quarter. Creative Planning now owns 26,440 shares of the medical technology company's stock valued at $276,000 after purchasing an additional 14,007 shares during the period. Lighthouse Investment Partners LLC increased its position in Alphatec by 257.5% during the 2nd quarter. Lighthouse Investment Partners LLC now owns 208,594 shares of the medical technology company's stock valued at $2,180,000 after purchasing an additional 150,244 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Alphatec by 8.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 58,257 shares of the medical technology company's stock worth $609,000 after purchasing an additional 4,755 shares in the last quarter. Marathon Capital Management bought a new stake in shares of Alphatec during the 2nd quarter valued at about $2,800,000. Finally, AQR Capital Management LLC increased its position in shares of Alphatec by 129.1% during the second quarter. AQR Capital Management LLC now owns 283,254 shares of the medical technology company's stock valued at $2,960,000 after buying an additional 159,600 shares during the period. 66.35% of the stock is currently owned by institutional investors.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.